<DOC>
	<DOCNO>NCT00806065</DOCNO>
	<brief_summary>The study design assess safety , tolerability , maximum tolerate dose , clinical benefit treatment ENMD-2076 administer orally daily range dose patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Study ENMD-2076 Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Major 1 . Histological evidence MM evidence relapse refractory disease . Patients non secretory myeloma plasmacytoma exclude . 2 . Patients must fail thalidomide , lenalidomide , velcade intolerant ineligible receive agent . 3 . Age â‰¥18 year . 4 . ECOG performance status 02 . 5 . Patients must adequate organ marrow function Major 1 . Prior cytotoxic chemotherapy investigational agent within 28 day autologous stem cell transplant within 6 month receive study drug ENMD2076 . 2 . Prior radiation therapy &gt; 25 % bone marrow form bone ( i.e. , pelvis ) . 3 . Concomitant corticosteroid therapy dose great 10 mg daily prednisone ( equivalent ) give management comorbid condition . 4 . Have unstable angina pectoris recent myocardial infarction ( within 6 month . 5 . Have uncontrolled hypertension congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>